Dear All: Two things today.
First, Ursula Theuretzbacher, Miloje Savic, Christine Ardal, and Kevin Outterson have published in Nature Reviews Drug Discovery a brief but instructive snapshot of the global preclinical antibacterial pipeline. This report nicely complements the recent WHO analysis of the clinical pipeline that concluded that "the world is running out of antibiotics."
You'll want to read the paper yourself (it's brief and open access), so I'll just summarize by saying that Ursula and colleagues have analyzed applications from Year 1 of the CARB-X initiative, found a good diversity of approaches, and observed that this shows an encouraging alignment with the WHO priority pathogen list. This is encouraging, but these preclinical programs have still a long way to go, will require a lot of support en route, and are of course high risk. Discovery is hard, so let's keep our fingers crossed!
Second, would you like to help fund a movie about antibiotic resistance? Bill Mudge, Jean Mudge, and Bob Milley are co-producers at Recombinant Films LLC. They have been steadily pulling together a internationally targeted documentary entitled Beating SuperBugs: Can We Win? for a generally educated but uninitiated audience. The documentary will focus on four of the CDC's top superbug threats: tuberculosis; MRSA; C. difficile; and CRE.
Using funds from a 2015 Kickstarter campaign, the team are now within about $100k of completing the film for release. If you'd like to help them get to done, you can make a tax-deductible contribution through their 501(c)3, non-profit fiscal sponsor, Catticus Corporation, Berkeley, CA. I think that non-technical material of this type is really valuable and I'm sure they'd appreciate any amount you might send.
All best wishes, --jr
John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog-index.html
Upcoming meetings of interest to the AMR community: